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Background. Bacterial meningitis is a major cause of mortality among children under 5 years of age. Senegal is part of World 
Health Organization–coordinated sentinel site surveillance for pediatric bacterial meningitis surveillance. We conducted this anal-
ysis to describe the epidemiology and etiology of bacterial meningitis among children less than 5 years in Senegal from 2010 and to 
2016.
Methods. Children who met the inclusion criteria for suspected meningitis at the Centre Hospitalier National d’Enfants Albert 
Royer, Senegal, from 2010 to 2016 were included. Cerebrospinal fluid specimens were collected from suspected cases examined by 
routine bacteriology and molecular assays. Serotyping, antimicrobial susceptibility testing, and whole-genome sequencing were 
performed.
Results. A total of 1013 children were admitted with suspected meningitis during the surveillance period. Streptococcus 
pneumoniae, Neisseria meningitidis, and Haemophilus accounted for 66% (76/115), 25% (29/115), and 9% (10/115) of all confirmed 
cases, respectively. Most of the suspected cases (63%; 639/1013) and laboratory-confirmed (57%; 66/115) cases occurred during the 
first year of life. Pneumococcal meningitis case fatality rate was 6-fold higher than that of meningococcal meningitis (28% vs 5%). 
The predominant pneumococcal lineage causing meningitis was sequence type 618 (n = 7), commonly found among serotype 1 iso-
lates. An ST 2174 lineage that included serotypes 19A and 23F was resistant to trimethoprim-sulfamethoxazole.
Conclusions. There has been a decline in pneumococcal meningitis post–pneumococcal conjugate vaccine introduction in 
Senegal. However, disease caused by pathogens covered by vaccines in widespread use still persists. There is need for continued ef-
fective monitoring of vaccine-preventable meningitis.
Keywords. pneumococcal conjugate vaccines; pediatric bacterial meningitis; Streptococcus pneumoniae; Haemophilus influenzae 
type b; Neisseria meningitidis.
Childhood bacterial meningitis remains a significant cause of 
morbidity and mortality worldwide [1–3]. In 2015 alone, men-
ingitis and sepsis ranked among the top 5 leading causes of 
mortality, causing an estimated 517  000 under-5 deaths [3, 4]. 
Sub-Saharan Africa has the largest burden of disease, bearing 
approximately half of the annual cases of meningitis that occur 
globally [2, 5, 6]. Beyond the neonatal period, the predominant 
causes of bacterial meningitis are Streptococcus pneumoniae 
(pneumococcus), Neisseria meningitidis (meningococcus), and 
Haemophilus influenzae type b (Hib) [6–11]. The third United 
Nations Sustainable Development Goals is to ensure healthy lives 
and promote well-being for all at all ages and targets to reduce 
under-5 mortality to fewer than 25 per 1000 live births by 2030 
[3]. Control of pneumococcus, meningococcus, and Hib is of par-
amount importance in achieving this goal in sub-Saharan Africa.
Immunization against pneumococcus, meningococcus, and 
Hib is one of the proven ways of reducing morbidity and mor-
tality of childhood bacterial meningitis [1, 12, 13]. In light of 
this, initiatives such as the Gavi, the Vaccine Alliance, and the 
Meningitis Vaccine Project (MVP) have led to the accelerated 
introduction of pneumococcal, Hib, and meningococcal con-
jugate vaccines in several African countries, including Senegal, 
during the last 10–15 years [12]. In Senegal, Hib vaccine was 
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introduced into the routine immunization program for children 
in 2005 as a primary 3-dose course at 2, 3, and 4 months with 
no booster. Similarly, the 13-valent pneumococcal conjugate 
vaccine (PCV-13) was introduced in 2014 without a catch-up 
in a 3  +  0 schedule, with doses given at 2, 3, and 4  months. 
Vaccine coverage rates remained high (>90%) for the Hib con-
jugate vaccine and above 80% for PCV-13 from 2014 to 2016. 
MenAfricVac mass campaigns targeting meningococcus sero-
group A (NmA) were conducted in 2013 for individuals aged 
1–29  years. However, assessing the impact of new vaccine is 
reliant on robust and high-quality surveillance data, which are 
lacking in many low-income countries including Senegal.
The World Health Organization (WHO) recommends im-
plementation of molecular tools in routine surveillance of inva-
sive bacterial vaccine-preventable diseases globally. In Senegal, 
this was facilitated by the WHO Regional Reference Laboratory 
(RRL), Medical Research Council (MRC) Unit The Gambia at 
the London School of Hygiene and Tropical Medicine. We con-
ducted this analysis to describe the epidemiology and etiology 
of bacterial meningitis among children less than 5 years of age 
in Senegal from 2010 and to 2016.
METHODS
Hospital-based sentinel surveillance of bacterial meningitis is 
ongoing at the Centre Hospitalier National d’Enfants Albert 
Royer (CHNEAR) located in Dakar, the capital city of Senegal. 
The CHNEAR is the largest pediatric referral facility in the 
country and receives patients from all secondary health facil-
ities nationwide. Senegal has an estimated population of 15.85 
million and a gross national per capita income of US $950 [14]. 
The human immunodeficiency virus prevalence is low, 0.08 
per 1000 persons, under 1% of the population The climate is 
tropical with well-defined dry and rainy seasons. The hot and 
dry Harmattan winds last from November until the onset of the 
rains in mid-May.
All children less than 5  years old who presented with sus-
pected meningitis between 2010 and 2016 underwent a lumbar 
puncture as part of the routine diagnostic procedures. A sus-
pected meningitis case was defined as sudden onset of fever 
(>38°C axillary or >38.5°C rectal temperature), with a combi-
nation of any of the following clinical symptoms: altered con-
sciousness, stiff neck, sensitivity to light and bulging of the 
fontanelle if the child is less than 1 year old; a confirmed case 
was defined as any suspected meningitis case that is laboratory 
confirmed by culture or polymerase chain reaction (PCR) [15]. 
For all recruited cases, information on demographic, clinical, 
and vaccination status was captured by trained surveillance 
personnel.
A detailed methodology of all bacteriological methods of ce-
rebrospinal fluid (CSF) collection has been reported elsewhere 
[16]. Briefly, CSF bacteriology was performed as previously 
described [17]. Following nucleic acid purification from CSF 
specimens, species-specific quantitative PCR (qPCR) for the 
detection of pneumococcus, meningococcus, and H. influenzae 
was performed [18–20]. A sequential multiplex qPCR assay for 
the detection of 21 different pneumococcal serotypes was per-
formed as described by Pimenta et al [21]. Cerebrospinal fluid 
specimens with CT values less than 32 that could not be typed by 
the 21-multiplex qPCR were subjected to an in-house conven-
tional PCR to detect additional serotypes (7C/7B/40, 15B/15C, 
17F, 8, 9N/9L, 24A/24B/24F, 21, 35F/47F, 13, 10F/10C/33C, 34, 
10A, 31) [16]. We employed the WHO pathogen-specific qPCR 
protocols to type/group H. influenzae and meningococcal [22].
Whole-genome sequencing was performed on genomic DNA 
extracted from 43 pneumococcal isolates using the Illumina 
HiSeq sequencer [23]. Sequencing reads from each isolate were 
mapped onto the S.  pneumoniae ATCC_700669 serotype 23F 
reference genome using SMALT [24] and pseudo-genomes 
placed in a multiple-sequence alignment using custom scripts. 
Single nucleotide polymorphisms (SNPs) were called from the 
pseudo-alignment using SNP sites, and a maximum likelihood 
phylogeny was reconstructed with a general time reversible 
model using Randomized Axelerated Maximum Likelihood 
(RAxML) [9]. The phylogenetic tree was visualized and anno-
tated using the interactive Tree of Life (iTOL) [25].
Statistical Analysis
Baseline characteristics of the study participants were summar-
ized using descriptive statistics. Proportions were based on the 
number of cases with available data for each variable. Univariate 
associations for clinical outcomes were assessed using χ 2 or 
Fisher’s exact tests where appropriate. Comparison of the clin-
ical outcomes and pathogen and serotype distribution between 
the pre–PCV-13 era (2010–2013) and the post–PCV-13 era 
(2014–2016) were performed using χ 2 or Fisher’s exact tests. 
Data were analyzed using STATA version 13 (StataCorp).
Ethical approval was not a requirement in Senegal for routine 
meningitis surveillance including drug susceptibility testing of 
collected isolates as this was approved within the routine diag-
nostic algorithm at the Ministry of Health. However, informed 
consent was sought from the parents or guardians of the sur-
veillance participants. Additionally, the surveillance received 
overarching ethical approval (SCC1188) by the joint MRC/The 
Gambia government ethics board that allowed the analysis of 
collected West African isolates at MRC Unit The Gambia.
RESULTS
A total of 1013 suspected meningitis cases were recruited at the 
CHNEAR sentinel site between January 2010 and December 
2016. The demographic and clinical characteristics of the 
children with suspected meningitis are summarized in Table 
1. The median age of study participants was 9  months (in-
terquartile range,  2.5–26  months), with most children aged 
less than 11 months (63% vs 37%, P <  .001). Nearly one-fifth 
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of the suspected cases had received antibiotic treatment prior 
to lumbar puncture. Outcome was reported for 90% (909 of 
1013) of the children, and the case fatality ratio among them was 
12.2%. More than half of the patients had a CSF specimen with 
a clear appearance (55%; 561 of 1010)  as well as white blood 
cell counts of 10 cells/mm3 or less (58%; 568 of 1010) (Table 1).
Overall, 99% (1010 of 1013) of CSF specimens were tested by at 
least 1 test (ie, rapid antigen tests, culture, or PCR). Almost one-
tenth of the CSF specimens tested by PCR (115 of 1010) showed 
laboratory-confirmed bacterial meningitis. Pneumococcus was 
the major pathogen detected, accounting for 66% (76 of 115) of 
all confirmed cases, followed by meningococcus (26%; 30 of 
115) and H. influenzae (9%; 9 of 115) (Figure 2).
Among the 39 confirmed pneumococcal meningitis cases, the 
dominant serotypes were 1, 5, 6A/6B, 7A/7F, 14, 19A, and 23F, all 
vaccine-type pneumococci (Figure 3). The highest proportions 
of pneumococci were detected in 2014, 1  year after introduc-
tion of PCV-13. However, a reduced number of pneumococcal 
meningitis cases were reported during 2015 (1 case) and 2016 (6 
cases), the last 2 years of the surveillance. There was a moderate 
increase in the number of nonvaccine serotypes (Figure 3).
Of the 29 confirmed meningococcal meningitis cases, speci-
mens for 12 were subjected to qPCR serogrouping and all be-
longed to serogroup W (NmW). Haemophilus influenzae type 
b accounted for nearly all (4 of 5) of all confirmed H. influenzae 
cases with a serotype result: 2 reported in 2014 and the other 2 
in 2016. Only half (2 of 4) of the reported Hib cases received all 
3 doses of Hib vaccine. The other H. influenzae isolate was type 
c (Hic).
Over half of all confirmed cases, 57% (66 of 115) were infants 
and pneumococci accounted for 76% (50 of 66). There were 7 
pneumococcal meningitis cases among neonates (<28 days). In 
contrast, two-thirds of meningococcal and H. influenzae men-
ingitis cases were among children 12 months of age and older. 
Case fatality rates were highest among infants aged 0–11 months 
(14%) compared with 11% and 7% among children aged 12 to 
23 months and 24 to 59 months, respectively. Pneumococcus 
also accounted for 94% (17 of 18) of the deaths. The other death 
was a child with meningococcal meningitis. None of the chil-
dren with H. influenzae meningitis died.
There was a decline in the number of suspected meningitis cases 
during the 7 years of surveillance, with just 86 suspected menin-
gitis cases reported in 2016 compared with 150 in 2010 when the 
surveillance started (Figure 2). Meningitis pathogens were more 
frequently detected during the dry windy Harmattan season of 
January to May compared with the wet season (Figure 4).
The CHNEAR sentinel site sent a total of 55 pneumococcal iso-
lates to the WHO RRL for confirmation, serotyping, antibiogram, 
and molecular characterization between 2010 and 2016 (Figure 
5). These isolates were primarily from CSF of suspected cases of 
Figure 1. Summary of CSF collection and processing for invasive bacterial disease surveillance in Senegal (2010–2016). Abbreviations: CSF, cerebrospinal fluid; PCR, 
polymerase chain reaction.
Table 1. Patient Characteristics of Suspected Bacterial Meningitis 
Cases (N = 1013)
Characteristic and category Total, n Percentage
Age   
 0–11 mo 639 63
 12–23 mo 165 16
 24–59 mo 208 21
 Unknown 1 0
Sex   
 Male 574 57
 Female 439 43
Antibiotic before admission   
 Yes 182 18
 No 731 72
 Unknown 100 10
Outcome   
 Discharged alive 798 79
 Died 111 11
 Unknown 104 10
Cerebrospinal fluid appearance   
 Clear 561 55
 Turbid 214 21
 Xanthochromic 114 11
 Blood stained 124 12
White blood cell   
 ≤10 cells/mm3 585 58
 >10 to 100 cells/mm3 176 17
 >100 cells/mm3 234 23
 Unknown 18 2
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meningitis (47 cases) but also included 8 non-CSF isolates col-
lected in 2009 for reference. One of the non-CSF isolates was 
cultured from a suspected meningitis case. Unfortunately, a case 
definition was not reported for the other 7 patients with a non-
CSF pneumococcal isolate. Whole-genome sequencing analysis 
revealed 2 major clades (Figure 5)—clade 1: serotypes 1, 5, 14, 
and 24; and clade 2: all other serotypes including some of sero-
type 14. We found that isolates belonging to the same serotype 
clustered together, particularly the predominant invasive sero-
types 1, 5, and 14. Sequence type (ST) 618 (n = 7) was the most 
common lineage among serotype 1 isolates, all of which were 
isolated prior to PCV-13 implementation in 2013. We noted an 
ST2174 lineage that included PCV-13 serotypes 19A and 23F, 
both of which were resistant to trimethoprim-sulfamethoxazole. 
Surprisingly, the other 23F serotype (ST9905) isolated was 
divergent to the 23F serotype (ST2174) that had clustered 
Figure 3. Temporal distribution of vaccine vs nonvaccine serotypes of pneumococcus by year (2010–2016). There was no serotyping result for all 5 pneumococcal menin-
gitis cases in 2013; the sentinel site did not send CSF specimens for these cases to the WHO RRL. Abbreviations: CSF, cerebrospinal fluid; PCV-13, 13-valent pneumococcal 
conjugate vaccine; RRL, Regional Reference Laboratory; WHO, World Health Organization.
Figure 2. Distribution of pathogens associated with pediatric bacterial meningitis in Senegal (2010–2016).
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with serotype 19A, and this showed multidrug resistance to 
trimethoprim-sulfamethoxazole, chloramphenicol, erythro-
mycin, and tetracycline. Among the isolates, high susceptibility 
to oxacillin and erythromycin was noted, while reduced suscep-
tibility to trimethoprim-sulfamethoxazole and tetracycline, and 
to a lesser extent chloramphenicol, was observed. None of iso-
lates was resistant to erythromycin. Compared with the pneu-
mococcal serotype 1 ST3081 isolates, ST618 isolates were more 
resistant to trimethoprim-sulfamethoxazole: 50% (3 of 6 cases) 
vs 86% (6 of 7 cases), respectively.
DISCUSSION
We present findings from 7  years of hospital-based sentinel 
surveillance of vaccine-preventable meningitis among children 
less than 5  years old in Senegal. Pneumococcus was the pre-
dominant etiologic agent among confirmed meningitis cases 
and was associated with high mortality in infants. There was 
a moderate decline in vaccine-type pneumococcal meningitis 
during the surveillance period. Haemophilus influenzae type b 
and NmW still remain important causes of bacterial meningitis 
among young children in Senegal despite the widespread use of 
conjugate vaccines.
In Senegal, Ba et al [26] reported (in descending order) sero-
types 6B, 19F, 23F, and 14 as the prevalent serotypes in nasopha-
ryngeal pneumococcal carriage and pneumococcal infection 
in children less than 5 years old between 2007 and 2008. This 
study confirmed a high rate of carriage and disease caused by 
pneumococcus serotypes contained within the current PCV 
formulations; the findings are also consistent with our surveil-
lance data where we report serotypes 1, 5, 6A/6B, 7F/7A, 14, 
and 23F as the predominant serotypes in Senegal prior to PCV-
13 introduction. The widespread use of PCVs has been shown 
to markedly reduce carriage of pneumococcal vaccine serotypes 
among both vaccinated and unvaccinated individuals [27–30]. 
PCV-13 was introduced into the Senegal Expanded Programme 
on Immunisation (EPI) in 2013. Although numbers were small, 
we showed a moderate reduction in the number of vaccine sero-
types after PCV-13 introduction. This finding is consistent with 
findings from a recent population-based study of invasive pneu-
mococcal disease in Senegal’s closest neighbor, The Gambia, 
which showed remarkable public health successes of PCVs asso-
ciated with a 55% reduction in invasive pneumococcal diseases 
in children aged 2–59  months [31]. Compared with baseline, 
the researchers reported a 55% decrease in the incidence of in-
vasive pneumococcal disease in the 2- to 23-month age group 
after PCV-13 introduction. This decrease was attributed to an 
82% reduction in serotypes covered by the PCV-13 vaccine. 
A similar trend was observed in the 2- to 4-year age group, with 
a 56% reduction in PCV-13 serotypes. However, the incidence 
of non–PCV-13 serotypes in children aged 2–59  months in-
creased by 47%, with a broad range of serotypes.
All serogrouped meningococci during the surveillance were 
NmW. Meningococcus serogroup W caused several sporadic 
meningitis cases in The Gambia in 1990s [32] and was also 
isolated during a serogroup A outbreak in Mali in 1994 [33]. 
Hossain et al [34] reported that NmW was the cause of the 2012 
meningitis outbreak in The Gambia, where a total of 469 sus-
pected cases were identified and 114 were confirmed NmW 
cases. Endemic NmW also persisted in South Africa between 
2000 and 2005, which is outside the meningitis belt. Although 
the numbers we report are small, the predominance of NmW 
Figure 4. Seasonality of meningitis pathogens in the Senegal (2010–2016).
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in Senegal supports the urgent need for a multivalent meningo-
coccal vaccine in this region. Fortunately, the development of a 
thermostable pentavalent meningococcal conjugate vaccine (A, 
C, Y, W-135, X) by the Serum Institute of India is underway. It 
is expected that this formulation will be cheaper and rolled out 
in African countries in the next 5 years. We are hopeful that this 
vaccine will eliminate meningococcal disease caused by sero-
groups covered by the vaccine in the African meningitis belt.
Unsurprisingly, there was no NmA meningitis throughout 
the 7 years of surveillance. The MenAfriVac mass vaccination 
campaigns conducted in countries of the meningitis belt, in-
cluding Senegal, are highly effective in prevention against sero-
group A invasive meningococcal disease and carriage. However, 
there are concerns about how long this protection will persist 
as well as the emergence of disease caused by other serogroups 
not included in the formulation [35]. As with the MenAfriVac, 
vaccination campaigns targeting NmW could be conducted in 
high-risk groups or, better still, the Gavi and MVP could work 
toward supporting the development of multivalent vaccines in-
cluding NmW in the routine EPI schedule for vulnerable popu-
lations in the meningitis belt.
Haemophilus influenzae type b was among the leading causes 
of bacterial meningitis in children younger than 5 years prior 
to the introduction of the Hib conjugate vaccine in Senegal 
[36]. The Hib vaccine introduced in 2005 in Senegal signifi-
cantly reduced the incidence of Hib meningitis and pneumonia. 
Hospital-based surveillance data from the CHNEAR between 
2002 and 2008 demonstrated the efficacy of Hib. The researchers 
reported a 98% reduction in the number of hospitalized Hib 
meningitis cases in 2008 compared with 2002. Similarly, intro-
duction of Hib in The Gambia’s Western region showed that it 
was 95% effective in preventing meningitis and bloodstream 
infection and 100% effective in preventing pneumonia [37]. 
Another study by Oluwalana et al [38] between 2007 and 2010 
Figure 5. Phylogeny and antibiogram of pneumococcal isolates associated with childhood bacterial meningitis in Senegal. Pneumococcal isolates include those from 2009 
(4 cases) to contextualize the isolates cultured from CSF specimens (39 cases). Resistance and intermediate resistance were confirmed by E-test. Abbreviations: C, chloram-
phenicol; CSF, cerebrospinal fluid; ERY, erythromycin; OX, oxacillin; PCV, pneumococcal conjugate vaccine; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline.
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found that the Hib conjugate vaccination as a primary 3-dose 
course in The Gambia remained highly effective in controlling 
invasive Hib disease. Recent data from Kenya showed that the 
use of a 3-dose primary series of Hib vaccine without a booster 
dose resulted in a significant and sustained reduction in Hib 
disease, suggesting that a booster dose is not currently required 
in Kenya. It is therefore concerning that Hib still causes bacte-
rial meningitis in Senegal, with 4 cases detected throughout the 
surveillance period.
Whole-genome sequencing analysis of pneumococcal iso-
lates showed that half of the serotype 1 strains belonged to 
ST618 [23], all of which were collected in the pre-PCV era. 
Post-PCV data from The Gambia has shown clonal replace-
ment of serotype 1 ST618 by ST3081 [39]. Given the heteroge-
neity and recombinogenic nature of pneumococcus, continued 
surveillance is key to understanding the temporal evolution of 
pneumococcus and the potential for serotype replacement.
Our finding of seasonality in meningitis-causing pathogens 
agrees with the pattern seen in the meningitis belt, with peaks 
in the first 5 months of the year [8, 34, 40].
Limitations
An important limitation of this surveillance is inherent in pas-
sive hospital-based identification of cases. It is likely that the 
data captured here are representative of urban/peri-urban chil-
dren. These data may not be representative of rural populations 
at greater risk of disease. Children with the most severe disease 
may indeed never reach Dakar and would not be captured in 
this surveillance. In addition, it would have been very useful to 
know what percentage of the pneumococcal meningitis cases 
had received PCV. Unfortunately, these data were not available 
for such an analysis. This report would have been enriched by 
the inclusion of more detailed data on sequelae. For instance, 
up to one-quarter (238) of all suspected meningitis cases had 
missing data on sequelae because these data were not recorded 
routinely among suspected meningitis cases. Only a very small 
proportion (11.5%) of the suspected cases were confirmed as 
meningitis cases.
Conclusions
Vaccine-preventable meningitis remains a major cause of child 
mortality and morbidity in Senegal. Enhanced surveillance for 
monitoring of vaccine impact and detection of meningitis is re-
commended for early detection of epidemics. There is a need 
to strengthen laboratory and surveillance capacity, which will 
enhance high-quality data capture on vaccine-preventable 
meningitis.
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